Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Austin Gold (AUST)
Intensity Therapeutics (INTS)
Genenta Science (GNTA)
Chicago Atlantic Real Estate Finance, Inc. (REFT)
Chicago Atlantic Real Estate Finance (REFI)
Nu Holdings Ltd. (NU)
Hashicorp, Inc. (HCP)
Fresh Vine Wine, Inc. (VINE)
Priced IPO
AeroClean Technologies (AERC)
Finwise Bancorp (FINW)
Kindercare Learning Companies, Inc. (KLC)
Snow Lake Resources (LITM)
Sweetgreen, Inc. (SG)
Usertesting, Inc. (USER)
Braze, Inc. (BRZE)
Sono Group N.v. (SEV)
Iris Energy Limited (IREN)
Mynaric Ag (MYNA)
Journey Medical Corporation? (DERM)
Tivic Health Systems (TIVC)
Blackboxstocks (BLBX)
Kidpik (PIK)
Vaxxinity, Inc. (VAXX)
Lulus Fashion Lounge Holdings, Inc. (LVLU)
Weave Communications, Inc. (WEAV)
Backblaze, Inc. (BLZE)
HeartBeam, Inc. (BEAT)
Rivian Automotive, Inc. (RIVN)
More companies

Xilio Therapeutics, Inc. (XLO)

Sector - Healthcare

Price chart

-17.56%
Return from IPO

Company News

IPO Profile

About company

They are a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. They have built their geographically precise solutions, or GPS, platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index by geographically localizing their activity inside tumors. Current immuno-oncology, or I-O, therapies have curative potential for patients with cancer; however, their potential is significantly curtailed by systemic toxicity that results from activity of the therapeutic molecule outside the tumor microenvironment, or TME. Their molecules are engineered to localize activity within the TME with minimal systemic effects, resulting in the potential to achieve enhanced anti-tumor activity. They are advancing a number of geographically precise, or tumor-selective, agents through various stages of development. Their most advanced product candidates are XTX101, an anti-cytotoxic T-lymphocyte-associated protein 4, or anti-CTLA-4, monoclonal antibody, or mAb, and XTX202, an interleukin 2, or IL-2, therapy. In June 2021, the U.S. Food and Drug Administration, or FDA, cleared their investigational new drug application, or IND, for XTX101, and they recently initiated their Phase 1 trial to evaluate XTX101 in patients with solid tumors.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
69 2015

Contacts

Address: 828 Winter Street, Suite 300 Waltham, Massachusetts 02451

Telephone: (617) 430-4680

Web page: http://www.xiliotx.com

IPO information

First Trade Date 10/22/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7.4
Shares Revised (MM) 7.35
Expected offer amount (MM) $124.95
Realized offer amount(MM) $117.6

Financial Data (last reporting year)

Market Cap (MM) $453.39
Revenues (MM) $0
Net Income (Loss) (MM) $-75.44

Voting

What do you think will happen with the XLO share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Morgan Stanley/ Cowen/ Guggenheim Securities
CO-Managers
Raymond James

Sector: Healthcare

Tweets about $XLO

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats